Therapeutic and Radiosensitizing Effects of Armillaridin on Human Esophageal Cancer Cells
Figure 5
Armillaridin inhibited the growth of esophageal cancer xenograft. Balb/c nude mice at 6 weeks of age were subcutaneously injected with 106 CE81T/VGH cells at day 0. Treatments were started on day 22 with triple administration per week for 12 doses. Data presented are mean SE (/group). The tumor size observed in the Armillaridin-treated group (80 mg/kg) was significantly decreased than in vehicle-treated group (a). There are no significant differences in body weight growth kinetic between control and Armillaridin-treated groups (b). No marked effect was observed in the white blood cell counts (c). AM: Armillaridin.
